- Home
- REFI vs FHTX Comparison
REFI vs FHTX Comparison
Compare REFI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- FHTX
- Stock Information
- Founded
- REFI 2021
- FHTX 2015
- Country
- REFI United States
- FHTX United States
- Employees
- REFI N/A
- FHTX N/A
- Industry
- REFI Real Estate Investment Trusts
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- REFI Real Estate
- FHTX Health Care
- Exchange
- REFI Nasdaq
- FHTX Nasdaq
- Market Cap
- REFI 306.1M
- FHTX 517.9M
- IPO Year
- REFI 2021
- FHTX 2020
- Fundamental
- Price
- REFI $15.39
- FHTX $7.55
- Analyst Decision
- REFI Buy
- FHTX Strong Buy
- Analyst Count
- REFI 2
- FHTX 5
- Target Price
- REFI $20.00
- FHTX $16.00
- AVG Volume (30 Days)
- REFI 73.0K
- FHTX 135.3K
- Earning Date
- REFI 11-07-2024
- FHTX 11-04-2024
- Dividend Yield
- REFI 12.22%
- FHTX N/A
- EPS Growth
- REFI N/A
- FHTX N/A
- EPS
- REFI 1.97
- FHTX N/A
- Revenue
- REFI $55,186,946.00
- FHTX $35,185,000.00
- Revenue This Year
- REFI N/A
- FHTX N/A
- Revenue Next Year
- REFI $4.51
- FHTX $15.40
- P/E Ratio
- REFI $7.81
- FHTX N/A
- Revenue Growth
- REFI 5.63
- FHTX 61.95
- 52 Week Low
- REFI $13.86
- FHTX $2.70
- 52 Week High
- REFI $17.65
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- REFI 42.89
- FHTX 45.26
- Support Level
- REFI $15.37
- FHTX $7.24
- Resistance Level
- REFI $15.85
- FHTX $8.35
- Average True Range (ATR)
- REFI 0.13
- FHTX 0.54
- MACD
- REFI -0.00
- FHTX -0.06
- Stochastic Oscillator
- REFI 22.22
- FHTX 43.20
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.